Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.60 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.53 |
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | FABP1 | P07148 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.50 |
| ▸ | ACSL1 | P33121 | 1/20 | 0.49 |
| ▸ | ACSL6 | Q9UKU0 | 1/20 | 0.49 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.49 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3175199 | 0.94 | FFAR4 (0.66) | FFAR1FFAR4NR4A2PDK2CYSLTR2 | |
| SCHEMBL1889231 | 0.89 | FFAR1 (0.56) | FFAR1FFAR4PPARANR4A2PDK2 | |
| SCHEMBL29757228 | 0.89 | FFAR1 (0.56) | FFAR1FFAR4PPARANR4A2PDK2 | |
| SCHEMBL30639265 | 0.89 | PPARA (0.58) | FFAR1FFAR4HDAC1HDAC2PPARA | |
| SCHEMBL4081340 | 0.83 | CNR2 (0.67) | HDAC1HDAC2PPARAFABP1ACSL1 | |
| SCHEMBL4076679 | 0.83 | CNR2 (0.67) | HDAC1HDAC2PPARAFABP1ACSL1 | |
| SCHEMBL4110127 | 0.83 | CNR2 (0.67) | HDAC1HDAC2PPARAFABP1ACSL1 | |
| SCHEMBL4114764 | 0.83 | CNR2 (0.67) | HDAC1HDAC2PPARAFABP1ACSL1 | |
| SCHEMBL2158881 | 0.83 | CNR2 (0.67) | HDAC1HDAC2PPARAFABP1ACSL1 | |
| SCHEMBL4086003 | 0.83 | CNR2 (0.67) | HDAC1HDAC2PPARAFABP1ACSL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268606-B1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-08-06 | — | — | EP | disclosed |
| US-8344027-B2 | 4-dimethylaminobutyric acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120289554-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | ANDJELKOVIC MIRJANA (CH) | 2012-11-15 | — | — | US | disclosed |
| EP-2268606-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009132978-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-05 | — | — | WO | disclosed |
| US-20090270505-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270505-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | CPT1B, CPT1A, CPT2 | FFAR1 162/4885FFAR4 190/4885HDAC1 360/4885 |
| US-20120289554-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | CPT1B, CPT1A, CPT2 | FFAR1 162/4885FFAR4 190/4885HDAC1 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.